Catherine A. Sohn
Catherine A. Sohn's purchase track record
Catherine A. Sohn has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/5/2026 | ALT | $2K | -18.6% | -24.7% | +9.2% |
| 3/17/2025 | ALT | $6K | +15.1% | -39.9% | +16.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Altimmune to attend Wells Fargo healthcare conference. Altimmune has been confirmed as a participant in the Wells Fargo 21st Annual Healthcare Conference. The company joins a roster of healthcare firms presenting at the event, which is a common venue for biopharma companies to engage with investors and outline pipeline progress. No new clinical, regulatory, or financial announcements accompanied the participation news, so the development is a routine scheduling item rather than a fundamental catalyst. As context, the stock has been trading well below the average analyst price target of $17.22, with its 52-week range between $2.56 and $6.44.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
JAZZ: Ziihera FDA win and leadership change shift company outlook. Jazz Pharmaceuticals recently received FDA approval for Ziihera and underwent a leadership change, which analysts suggest may alter the investment case. The company is also diversifying its portfolio, changing the narrative around its earnings. While the stock is currently trading near its 52-week low, the average analyst target price remains significantly higher than the current market level.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Lifecore Biomedical to be acquired by Webster Equity Partners. Lifecore Biomedical has announced it will be acquired by Webster Equity Partners in a deal valued at up to $663.7 million. Shareholders may receive up to $9.67 per common equivalent, combining cash and contingent value rights based on performance milestones. This transaction is significant as it represents a full exit for the company, with the potential payout exceeding the current average analyst target of $6.75.
Transaction History
| MAZE | ▲ Buy | Option Exercise | 20,744 | $216K | 1/7/2026 | View on chart |
| MAZE | ▲ Buy | Option Exercise | 2,895 | $30K | 1/7/2026 | View on chart |
| MAZE | ▲ Buy | Option Exercise | 3,281 | $34K | 1/7/2026 | View on chart |
| MAZE | ▼ Sell | Open Market | 26,920 | $1.1M | 1/7/2026 | View on chart |
| MAZE | ▲ Buy | Option Exercise | 2,493 | $26K | 1/6/2026 | View on chart |
| MAZE | ▼ Sell | Open Market | 2,493 | $96K | 1/6/2026 | View on chart |
| ALT | ▲ Buy | Open Market | 500 | $2K | 1/5/2026 | View on chart |
| ALT | ▲ Buy | Open Market | 1,000 | $6K | 3/17/2025 | View on chart |
| JAZZ | ▼ Sell | Open Market | 1,241 | $171K | 8/14/2023 | View on chart |
| JAZZ | ▲ Buy | Grant | 3,075 | $0 | 8/11/2023 | View on chart |
| JAZZ | ▼ Sell | Open Market | 1,089 | $166K | 8/8/2022 | View on chart |
| JAZZ | ▲ Buy | Grant | 2,561 | $0 | 8/5/2022 | View on chart |
| LFCR | ▲ Buy | Grant | 7,059 | $67K | 6/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Pompe Disease Market Expected to Grow Through 2036
A new market report projects expansion in the Pompe Disease sector from 2026 to 2036, driven by next-generation enzyme replacement therapies and pipeline innovation. This industry growth is relevant to Maze Therapeutics, which operates in this therapeutic area. The report highlights broader market trends rather than company-specific financial results.
Pompe Disease Market Expected to Grow Through 2036. A new market report projects expansion in the Pompe Disease sector from 2026 to 2036, driven by next-generation enzyme replacement therapies and pipeline innovation. This industry growth is relevant to Maze Therapeutics, which operates in this therapeutic area. The report highlights broader market trends rather than company-specific financial results.